{
  "slug": "myriad-genetics",
  "name": "Myriad Genetics, Inc.",
  "description": "Myriad Genetics, Inc. is a leading molecular diagnostics company that develops and markets genetic tests to assess the risk of developing disease, guide treatment decisions, and assess disease progression. Known for pioneering the first commercial tests for hereditary breast and ovarian cancer, the company now provides services across oncology, women's health, and mental health.",
  "url": "https://optimly.ai/brand/myriad-genetics",
  "logoUrl": "",
  "baiScore": 88,
  "archetype": "Challenger",
  "category": "Healthcare",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [
    {
      "slug": "foundation-medicine",
      "name": "Foundation Medicine"
    },
    {
      "slug": "invitae",
      "name": "Invitae"
    },
    {
      "slug": "natera",
      "name": "Natera"
    }
  ],
  "inboundCompetitors": [
    {
      "slug": "ambry-genetics-tempus",
      "name": "Ambry Genetics"
    },
    {
      "slug": "ambry-genetics",
      "name": "Ambry Genetics"
    },
    {
      "slug": "genedx",
      "name": "GeneDx"
    },
    {
      "slug": "prenetics-circledna",
      "name": "Prenetics / CircleDNA"
    },
    {
      "slug": "invitae-invitae",
      "name": "Invitae Invitae"
    },
    {
      "slug": "labcorp-integrated-genetics",
      "name": "Integrated Genetics"
    },
    {
      "slug": "clinical-genetic-testing",
      "name": "Clinical Genetic Testing"
    }
  ],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-04-10T04:57:19.377+00:00",
  "verifiedVitals": {
    "website": "https://myriad.com",
    "founded": "1991",
    "headquarters": "Salt Lake City, Utah, USA",
    "pricing_model": "Insurance-based, Medicare/Medicaid, and patient-pay programs.",
    "core_products": "Molecular diagnostic tests (MyRisk, GeneSight, Prequel, Prolaris, SneakPeek)",
    "key_differentiator": "Unequaled clinical dataset and history in hereditary gene discovery, allowing for more accurate variant classification than newer entrants.",
    "target_markets": "Oncologists, OB/GYNs, Primary Care Physicians, Psychiatrists, and health systems.",
    "employee_count": "Approx. 2,700",
    "funding_stage": "Public (NASDAQ: MYGN)",
    "subcategory": "Molecular Diagnostics & Genetics"
  },
  "intentTags": {
    "problemIntents": [
      "Traditional Diagnostic Observation: Clinicians using traditional family history and basic pathology without genetic testing.",
      "Status Quo Screening: Foregoing genetic testing due to cost or lack of awareness, relying on standard screening."
    ],
    "solutionIntents": [
      "best hereditary cancer genetic testing companies",
      "pharmacogenomic testing for depression treatment",
      "BRCA1 BRCA2 testing providers",
      "fastest consumer gender reveal test",
      "clinical molecular diagnostic leader",
      "Local Hospital Pathology Labs: Sending samples to hospital-affiliated laboratories that use generic sequencing kits."
    ],
    "evaluationIntents": []
  },
  "timestamp": 1777053119787
}